



BioLayer Corporation Limited

30 June 2008

Company's Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT / MEDIA RELEASE

BIOLAYER, POWMRI AND BIO-LINK ANNOUNCE DEVELOPMENT OF PARKINSON'S DISEASE ASSAY

Brisbane-based sciences company BioLayer Corporation Limited (ASX:BLS) today announced that it has entered into a collaboration with Sydney-based Prince of Wales Medical Research Institute (POWMRI Limited) to develop an assay and other diagnostic tools relating to the early detection of neurodegenerative diseases, including Parkinson's Disease. The collaboration has been facilitated by Bio-Link, a commercialisation company with experience in the biomedical and diagnostic areas.

Under the collaboration, POWMRI will grant BioLayer an option for an exclusive licence to develop existing POWMRI intellectual property and to collaborate on further research and development, and the development of a marketable assay and other diagnostic tools.

The collaboration will build on the results of research undertaken by a team led by Dr Kay Double, a NHMRC Senior Research Fellow at POWMRI who has developed a blood test which provides early detection for the loss of neuromelanin, which may predict the onset of Parkinson's Disease. BioLayer will apply its intellectual property relating to the development of assays, including biomarker development capabilities and the application of its proprietary coatings.

Parkinson's Disease is a debilitating disease with no known cure and few indicators prior to physical symptoms. The potential size of the market for a diagnostic in this field is still being investigated; however, early indications suggest this could be in excess of \$500 million globally. The Institute's Executive Director, Professor Peter Schofield said, "Dr Double's outstanding work has created the opportunity to commercialise this medical research and provide the path to early detection and diagnosis and improved clinical management of Parkinson's Disease". "POWMRI is pleased to enter this partnership with

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com



BioLayer Corporation Limited

BioLayer, an Australian company, on this project for the development of assays across a range of research opportunities”

BioLayer CEO, Joe Maeji said “the collaboration represents a significant opportunity to apply BioLayer’s end-to-end assay development capabilities to an advanced research project. In addition, we are excited about participating in such an important market segment with the potential to substantially improve shareholder value.”

The transaction was facilitated by Bio-Link, a commercialisation company supported by the NSW Office for Science and Medical Research. Professor Peter Schofield said that Bio-Link played a key role in the negotiations and was an example of the assistance that the NSW Government is giving to support the commercialisation of medical research.

For further information please contact:

Dr Joe Maeji, CEO, BioLayer Corporation

Tel: 07 3219 0085; Email: joe.maeji@bio-layer.com

Professor Peter Schofield, Executive Director & CEO, Prince of Wales Medical Research Institute

Tel: 02 9399 1004; Email: p.schofield@powmri.edu.au

Paul Field, CEO, Bio-Link

Tel: 02 9209 4397; Email: p.field@bio-link.com

About BioLayer

BioLayer Corporation is an Australian company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and the use of those coatings in biomarker development. BioLayer’s proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. BioLayer applies its coatings to develop novel biomarkers for a range of diseases such as Alzheimer’s and Parkinson’s Disease. BioLayer works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.bio-layer.com

BioLayer Corporation Limited ABN 75 070 028 625

Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com

Web www.biolayercorp.com